DOI: https://doi.org/10.36347/sajb.2026.v14i01.003

Pages: 60-73

Cardiovascular disease (CVD) is a serious principal cause of death globally thrusting a huge economic load. There is no diagnostic and therapeutic strategy for the prevention of CVD. MiRNAs have been reported to play a significant role in cardiovascular pathologies. MicroRNA-132 (miR-132) is involved in cardiac apoptosis, impaired calcium handling, cardiac hypertrophy, pathological cardiac remodelling, oxidative stress, and angiogenesis. These cardiac pathophysiological effects are caused by miR-132-mediated downregulation of SIRT1, FoxO3, SERCA2A, and PTEN target gene expression. CDR-132L and other antimiR-132 long non-coding RNAs significantly inhibited miR-132 expression in pathophysiological cardiac remodelling and also cardiac apoptosis. These miR-132 targeting approaches can have great therapeutic potential. Present review intended to highlight the therapeutic and biomarker potential of miR-132 in the diagnosis and treatment of CVD various types. The potential clinical benefits of miR-132 inhibition through CDR-132L and other antimiR-132 long non-coding antisense oligonucleotides strategies have also been highlighted.